|Articles|May 1, 2000

May 2000
Volume 6
Issue 5

Proton Pump Inhibitor Therapy: Preliminary Results of a Therapeutic Interchange Program

Author(s)Phillip B. Amidon, MD, Rhonda Jankovich, RN, BSN, Cheryl A. Stoukides, PharmD

Download PDF: Proton Pump Inhibitor Therapy: Preliminary Results of a Therapeutic Interchange Program

Articles in this issue

about 26 years ago

Article

Training Tomorrow's Clinicians Today - Managed Care Essentials: A Process for Curriculum Development

about 26 years ago

Article

Relationship of Hemoglobin A1C, Age of Diabetes Diagnosis, and Ethnicity to Clinical Outcomes and Medical Costs in a Computer-Simulated Cohort of Persons with Type 2 Diabetes

about 26 years ago

Article

Disease Management Program Improves Asthma Outcomes

about 26 years ago

Article

Prescribing Medications for Geriatric Patients in the Managed Care Setting

about 26 years ago

Article

The Inpatient Specialist: What is the Difference?

about 26 years ago

Article

Teaching Managed Care Principles: We Need to Do Better

about 26 years ago

Article

The Impact of an Inpatient Physician Program on Quality, Utilization, and Satisfaction

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Proton Pump Inhibitor Therapy: Preliminary Results of a Therapeutic Interchange Program

Articles in this issue

Related Content

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Trending on AJMC

FDA Approves Enlicitide, First Oral PCSK9 for High Cholesterol

FTC Reaches Settlement With CVS Caremark to Curb Insulin Rebate Practices, Cut Patient Costs

Remote Monitoring Captured Between-Visit Symptom Swings in Myasthenia Gravis

SNAP Participation Linked to Smaller Colorectal Screening Gap

Innovation Is Outpacing Reimbursement, Health System Execs Warn